Evidence map›Paper›PMID 27903633›Full record

ArticleThe Journal of biological chemistry2017

An E2-guided E3 Screen Identifies the RNF17-UBE2U Pair as Regulator of the Radiosensitivity, Immunodeficiency, Dysmorphic Features, and Learning Difficulties (RIDDLE) Syndrome Protein RNF168.

Yingying Guo, Liwei An, Hoi-Man Ng, Shirley M H Sy, Michael S Y Huen

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yingying GuoFrom the School of Biomedical Sciences, Li Ka Shing Faculty of Medicine and.
Liwei AnFrom the School of Biomedical Sciences, Li Ka Shing Faculty of Medicine and.
Hoi-Man NgFrom the School of Biomedical Sciences, Li Ka Shing Faculty of Medicine and.
Shirley M H SyFrom the School of Biomedical Sciences, Li Ka Shing Faculty of Medicine and mhsy@hku.hk.
Michael S Y HuenFrom the School of Biomedical Sciences, Li Ka Shing Faculty of Medicine and huen.michael@hku.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein ubiquitination has emerged as a pivotal regulatory reaction that promotes cellular responses to DNA damage. With a goal to delineate the DNA damage signal transduction cascade, we systematically analyzed the human E2 ubiquitin- and ubiquitin-like-conjugating enzymes for their ability to mobilize the DNA damage marker 53BP1 onto ionizing radiation-induced DNA double strand breaks. An RNAi-based screen identified UBE2U as a candidate regulator of chromatin responses at double strand breaks. Further mining of the UBE2U interactome uncovered its cognate E3 RNF17 as a novel factor that, via the radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties (RIDDLE) syndrome protein RNF168, enforces DNA damage responses. Our screen allowed us to uncover new players in the mammalian DNA damage response and highlights the instrumental roles of ubiquitin machineries in promoting cell responses to genotoxic stress.

Indexed as

DNA Breaks, Double-StrandedUbiquitinationChromatinHeLa CellsHumansTranscription FactorsTumor Suppressor p53-Binding Protein 1UbiquitinUbiquitin-Protein LigasesChromatinRNF168 protein, humanTP53BP1 protein, humanTranscription FactorsTumor Suppressor p53-Binding Protein 1UbiquitinUbiquitin-Protein LigasesDNA damage responseE3 ubiquitin ligaseRNA interference (RNAi)small interfering RNA (siRNA)ubiquitinubiquitin-conjugating enzyme (E2 enzyme)

Identifiers

PMID27903633
PMCPMC5247668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.